In a flame dried round bottom flask 10.0 g dC (44.0 mmol, 1.0 eq), 7.70 g iodine (26.4 mmol, 0.6 eq) and 11.4 g mCPBA (70 %, 46.2 mmol, 1.05 eq) were dissolved in 120 mL DMF. The reaction mixture was stirred 2 h at room temperature and subsequently evaporated to dryness. Purification by column chromatography (DCM/MeOH/H₂O/NH₃ 190:10:0.6:0.6 → 90:10:0.6:0.6) yielded 9.71 g (63 %) of 5 as an orange solid.

¹H NMR (400 MHz, CDCl₃/MeOD) δ (ppm) = 8.46 (s, 1H), 6.13 (t, ³J=6.0, 1H), 4.34 (dt, ³J=4.7, ³J=6.3 , 1H), 3.93 (dt, ³J=3.0, ³J=4.3, 1H), 3.84 (dd, ³J=3.0 Hz, ²J=12.1, 1H), 3.72 (dd, ³J=3.2, ²J=12.1, 1H), 2.39 (ddd, ³J=4.8, ³J=6.3, ²J=13.7, 1H), 2.20 – 2.09 (m, 1H). ¹³C NMR (101 MHz, MeOD) δ (ppm) = 163.9, 153.9, 150.9, 89.5, 88.3, 71.5, 62.2, 56.2, 42.5. HRMS (ESI +) calculated for C₉H₁₃I₂N₃O₄⁺ [M+H]⁺: 353.9945, found: 353.9944.

In a flame dried round bottom flask 5.00 g 5 (13.5 mmol, 1.0 eq), 4.16 g imidazole (60.5 mmol, 4.5 eq) and 6.24 g (40.4 mmol, 3.0 eq) TBS-Cl were dissolved in 80 mL
DMF and stirred at RT for 16 h. Subsequently the reaction was stopped by the addition of 150 mL sat. NaHCO₃ and extracted with 300 mL chloroform. The organic layers were washed with 300 mL H₂O, dried over MgSO₄ and the solvent removed in vacuo. The crude product was purified by column chromatography (DCM/MeOH 99:1 → 49:1) to yield 6.25 g (80 %) of 1 as a slightly yellow solid.

1H NMR (400 MHz, CDCl₃) δ (ppm) = 8.06 (s, 1H), 6.25 – 6.19 (m, 1H), 4.34 (dt, 3J=2.9, 3J=5.9, 1H), 3.97 (q, 3J=2.6, 1H), 3.87 (dd, 3J=2.6, 2J=11.4, 1H), 3.74 (dd, 3J=2.6, 2J=11.4, 1H), 2.44 (ddd, 3J=3.0, 3J=5.9, 2J=13.3, 1H), 2.00 – 1.90 (m, 1H), 0.92 (s, 9H), 0.87 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (101 MHz, CDCl₃) δ (ppm) = 163.2, 154.3, 146.7, 88.3, 86.8, 72.2, 62.8, 56.2, 42.6, 26.1, 25.7, 18.5, 18.0, -4.6, -4.9, -5.2, -5.3. HRMS (ESI+): calculated for C₂₁H₄₄IN₅O₄Si₂⁺ [M+H]⁺: 582.1675, found: 582.1683.

In a high pressure glass autoclave 3.50 g 1 (6.02 mmol, 1.0 eq), 947 mg PPh₃ (3.61 mmol, 0.6 eq) and 623 mg Pd₂(dba)₃·CHCl₃ (0.60 mmol, 0.1 eq) were dissolved in 90 mL toluene. The autoclave was flushed with CO twice to remove residual air and subsequently the reaction stirred at a CO pressure of 3.5 bar at 60 °C. With a syringe pump 2.02 mL Bu₃SnH (7.22 mmol, 1.2 eq) were added through a septum at 0.3 mL per hour. After complete addition the reaction mixture was stirred additional 12 hours at 60 °C. Subsequently the CO was discharged and the solvent evaporated in vacuo. The crude product was purified by column chromatography (iHex/EtOAc 4:1→2:1→1:1) to yield 2.84 g (97 %) 2 as a yellow solid.

1H NMR (300 MHz, CDCl₃) δ (ppm) = 9.51 (s, 1H), 8.57 (s, 1H), 8.37 (s, 1H), 7.46 (s, 1H), 6.19 (t, 3J=6.1, 1H), 4.40 – 4.32 (m, 1H), 4.08 – 4.02 (m, 1H), 3.95 (dd, 3J=2.7,
$^{2}J=11.7$, 1H), 3.78 (dd, $^{3}J=2.6$, $^{2}J=11.6$, 1H), 2.59 (ddd, $^{3}J=3.6$, $^{3}J=5.8$, $^{2}J=10.3$, 1H), 2.20 – 2.08 (m, 1H), 0.89 (s, 9H), 0.88 (s, 9H), 0.10 (s, 3H), 0.08 (s, 6H), 0.07 (s, 3H).

$^{13}$C NMR (75 MHz, CDCl$_3$) δ (ppm) = 187.1, 162.1, 153.1, 152.6, 104.9, 88.8, 87.9, 71.5, 62.6, 42.8, 25.9, 25.7, 18.4, 17.9, -4.5, -4.9, -5.2, -5.4. HRMS (ESI+): calculated for C$_{22}$H$_{44}$N$_{3}$O$_{5}$Si$_{2}$ $^{[M+H]}$: 484.2658, found: 484.2654.

In a flame dried round bottom flask 300 mg 2 (0.62 mmol, 1.0 eq) and 707 mg CeCl$_3$·7 H$_2$O (1.86 mmol, 3.0 eq) were dissolved in 30 mL methanol. To this solution 24 mg NaBH$_4$ (0.62 mmol, 1.0 eq) were added and the mixture stirred at room temperature for 30 min. The reaction was stopped by addition of 100 mL sat. NH$_4$Cl and extracted with 100 mL EtOAc. Subsequently the organic layers were washed twice with 100 mL NH$_4$Cl, dried over MgSO$_4$, evaporated to dryness and the crude product purified by column chromatography (DCM/MeOH 19:1, dry loaded) to yield 184 mg 7 (61 %) as a colorless oil.

$^{1}$H NMR (599 MHz, CDCl$_3$) δ (ppm) = 7.59 (s, 1H), 6.13 (t, $^{3}J=6.4$, 1H), 4.39 (d, $^{2}J=13.1$, 1H), 4.36 (d, $^{2}J=13.1$, 1H), 4.30 (dt, $^{3}J=3.5$, $^{3}J=6.6$, 1H), 3.90 (q, $^{3}J=3.1$, 1H), 3.81 (dd, $^{3}J=3.2$, $^{2}J=11.2$, 1H), 3.72 (dd, $^{3}J=3.0$, $^{2}J=11.3$, 1H), 2.36 (ddd, $^{3}J=3.6$, $^{3}J=6.1$, $^{2}J=13.3$, 1H), 1.93 (dt, $^{3}J=6.5$, $^{2}J=13.2$, 1H), 0.88 (s, 9H), 0.87 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H). $^{13}$C NMR (151 MHz, CDCl$_3$) δ (ppm) = 165.2, 156.2, 138.6, 106.0, 87.8, 86.2, 71.7, 62.7, 59.5, 42.2, 25.9, 25.8, 18.4, 18.0, -4.6, -4.9, -5.3, -5.4. HRMS (ESI+): calculated for C$_{22}$H$_{44}$N$_{3}$O$_{5}$Si$_{2}$ $^{[M+H]}$: 486.2814, found: 484.2815.
In a flame dried round bottom flask 100 mg 7 (0.21 mmol, 1.0 eq) were dissolved in 10 mL THF and 410 µL TBAF (1M in THF, 0.41 mmol, 2.0 eq) added. The solution was stirred at room temperature for 3 h. Subsequently 1 mL TMSOMe was added and the reaction mixture stirred for 30 min. The solvents were evaporated *in vacuo* and the crude product purified by HPLC (0-20 % MeCN in 45 min) to yield 27 mg (51 %) hmC as a colorless solid.

\( ^1H \text{ NMR (400 MHz, D}_2\text{O/MeOD)} \delta (\text{ppm}) = 7.83 (s, 1H), 6.16 (t, ^3J=6.5, 1H), 4.42 - 4.25 (m, 3H), 3.95 (dd, ^3J=3.7, ^3J=8.5, 1H), 3.76 (dd, ^3J=3.4, ^2J=12.5, 1H), 3.67 (dd, ^3J=4.8, ^2J=12.5, 1H), 2.34 (ddd, ^3J=4.1, ^3J=6.4, ^2J=14.0, 1H), 2.24 - 2.11 (m, 1H). \)

\( ^{13}C \text{ NMR (101 MHz, D}_2\text{O/MeOD)} \delta (\text{ppm}) = 166.1, 158.3, 141.3, 107.8, 88.0, 87.3, 71.6, 62.3, 59.0, 41.0. \) HRMS (ESI-): calculated for C\(_{10}\)H\(_{14}\)N\(_3\)O\(_5\) \([M-H]\): 256.0939, found: 256.0936.

In a high pressure glass autoclave 200 mg 1 (0.34 mmol, 1.0 eq), 54 mg PPh\(_3\) (0.21 mmol, 0.6 eq) and 36 mg Pd\(_2\)(dba)\(_3\)*CHCl\(_3\) (0.03 mmol, 0.1 eq) were dissolved in 8
mL deuterio-benzene. The autoclave was flushed with CO twice to remove residual air and subsequently the reaction stirred at a CO pressure of 3.5 bar at 60 °C. With a syringe pump 116 µL Bu₃SnH (0.41 mmol, 1.2 eq, diluted with 850 µL deuterio-benzene) were added through a septum at 0.1 mL per hour. After complete addition the reaction mixture was stirred additional 12 hours at 60 °C. Subsequently the CO was discharged and the solvent evaporated in vacuo. The crude product was purified by column chromatography (iHex/EtOAc 4:1→2:1→1:1) to yield 82 mg (49 %) 8 as a yellow solid.

¹H NMR (300 MHz, CDCl₃) δ (ppm) = 8.52 (s, 1H), 8.18 (s, 1H), 7.04 (s, 1H), 6.19 (t, ³J=6.1, 1H), 4.38 – 4.31 (m, 1H), 4.03 (dd, ³J=2.6, ³J=5.6, 1H), 3.94 (dd, ³J=2.6, ²J=11.6, 1H), 3.77 (dd, ³J=2.5, ²J=11.6, 1H), 2.60 (ddd, ³J=3.8, ³J=6.1, ²J=13.6, 1H), 2.06 (dt, ³J=6.1, ²J=9.6, 1H), 0.88 (2x s, 18H), 0.09 (s, 3H), 0.07 (s, 6H), 0.05 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ (ppm) = 186.5, 162.7, 153.3, 152.8, 104.9, 88.5, 87.6, 71.5, 62.5, 42.9, 25.9, 25.7, 18.4, 17.9, -4.6, -5.0, -5.3, -5.4. HRMS (ESI-): calculated for C₂₂H₃₉DN₃O₅Si₂-[M-H]⁻: 483.2575, found: 483.2569.

In a flame dried round bottom flask 75 mg 8 (0.15 mmol, 1.0 eq) and 176 mg CeCl₃·7 H₂O (0.46 mmol, 3.0 eq) were dissolved in 5 mL deuterio-methanol. To this solution 7 mg NaBD₄ (0.15 mmol, 1.0 eq) were added and the mixture was stirred at room temperature for 15 min. The reaction was stopped by the addition of 50 mL sat. NH₄Cl and extracted with 50 mL EtOAc. Subsequently the organic layers were washed twice with 50 mL NH₄Cl, dried over MgSO₄, evaporated to dryness and the
crude product purified by column chromatography (DCM/MeOH 19:1, dry loaded) to yield 16 mg 9 (21 %) as a colorless oil.

$^1$H NMR (300 MHz, CDCl$_3$) $\delta$ (ppm) = 7.61 (s, 1H), 6.14 (t, $^3$J=6.4, 1H), 4.31 (dt, $^3$J=3.1, $^2$J=11.1, 1H), 3.72 (dd, $^3$J=2.9, $^2$J=11.2, 1H), 2.38 (ddd, $^3$J=3.5, $^3$J=6.2, $^2$J=13.4, 1H), 1.94 (dt, $^3$J=6.6, $^2$J=13.2, 1H), 0.89 (2x s, 18H), 0.08 (2x s, 6H), 0.05 (2x s, 6H). $^{13}$C NMR (75 MHz, CDCl$_3$) $\delta$ (ppm) = 165.2, 156.2, 138.6, 105.8, 87.8, 86.3, 71.7, 62.7, 58.3, 42.2, 25.9, 25.8, 18.37, 18.0, -4.6, -4.9, -5.3, -5.4. HRMS (ESI+): calculated for C$_{22}$H$_{42}$D$_2$N$_3$O$_5$Si$_2^+\ [M+H]^+$: 488.2940, found: 488.2941.

In a polypropylene tube 16 mg 9 (0.03 mmol, 1.0 eq) were dissolved in 2 mL EtOAc, subsequently 14 µL pyridine (0.17 mmol, 5.0 eq) and 14 µL HF*pyridine (70 % HF, 0.52 mmol, 15.0 eq) were added and the reaction mixture stirred 14 h at room temperature. During this time a white solid precipitated. 500 µL TMSOMe were added and the reaction mixture stirred another 30 min. Subsequently the solid was collected by centrifugation (6000 rpm, 15 min). The crude product was purified by HPLC (0-25 % MeCN in 45 min) to yield 10 mg [D$_2$]-hmC (94 %) as a colorless solid.

$^1$H NMR (400 MHz, D$_2$O/MeOD) $\delta$ (ppm) = 7.92 (s, 1H), 6.28 (t, $^3$J=6.6, 1H), 4.46 (dt, $^3$J=3.5, $^3$J=6.1, 1H), 4.07 (dd, $^3$J=3.2, $^3$J=6.7, 1H), 3.88 (dd, $^3$J=3.3, $^2$J=12.5, 1H), 3.79 (dd, $^3$J=4.9, $^2$J=12.8, 1H), 2.46 (ddd, $^3$J=4.0, $^3$J=6.4, $^2$J=12.7, 1H), 2.32 (dt, $^3$J=7.0, $^2$J=14.2, 1H). $^{13}$C NMR (101 MHz, D$_2$O/MeOD) $\delta$ (ppm) = 166.1, 158.4, 141.6, 107.7, 87.8, 87.3, 71.5, 62.2, 53.4, 40.5. HRMS (ESI+): calculated for C$_{10}$H$_{13}$D$_2$N$_3$NaO$_5^+\ [M+Na]^+$: 282.1029, found: 282.1030.
In a polypropylene tube 400 mg 2 (0.78 mmol, 1.0 eq) were dissolved in 30 mL EtOAc, subsequently 316 µL pyridine (3.91 mmol, 5.0 eq) and 305 µL HF\*pyridine (70 % HF, 11.7 mmol, 15.0 eq) were added at 0°C and the reaction mixture stirred 14 h at room temperature. During this time a white solid precipitated. 3 mL TMSOMe were added and the reaction mixture stirred another 30 min. Subsequently the solid was collected by centrifugation (4000 rpm, 15 min) yielding 165 mg (75 %) fC. Although the product was pure according to NMR, it was subjected to HPLC purification (0-25 % MeCN in 45 min) before it was used as a standard for the mass spectrometry experiments.

\(^1\)H NMR (400 MHz, D\(_2\)O/MeOD) \(\delta\) (ppm) = 9.56 (s, 1H), 8.85 (s, 1H), 6.24 (t, \(^3\)J=6.1, 1H), 4.48 (dt, \(^3\)J=4.8, \(^3\)J=6.5, 1H), 4.18 (dd, \(^3\)J=4.6, \(^3\)J=8.0, 1H), 3.96 (dd, \(^3\)J=3.4, \(^2\)J=12.6, 1H), 3.84 (dd, \(^3\)J=4.9, \(^2\)J=12.6, 1H), 2.62 (ddd, \(^3\)J=4.9, \(^3\)J=6.5, \(^2\)J=14.1, 1H), 2.46 – 2.37 (m, 1H). \(^13\)C NMR (101 MHz, D\(_2\)O/MeOD) \(\delta\) (ppm) = 190.3, 162.6, 155.2, 154.6, 105.7, 87.4, 87.1, 69.7, 60.6, 40.0. HRMS (ESI+): calculated for C\(_{10}\)H\(_{14}\)N\(_3\)O\(_5\)^+ [M+H]^+: 256.0928, found: 256.0928.
In a high pressure glass autoclave 1.00 g 1 (1.72 mmol, 1.0 eq), 49 mg PdCl₂(MeCN)₂ (0.19 mmol, 0.11 eq) and 600 µL DIPEA (3.44 mmol, 2.0 eq) were dissolved in 10 mL TMS-Et-OH. The autoclave was flushed with CO twice to remove residual air and subsequently the reaction stirred at a CO pressure of 3.5 bar at 60 °C for 24 h. After completion of the reaction the CO was discharged and the solvent evaporated in vacuo. The crude product was purified by column chromatography (iHex/EtOAc 4:1→2:1) to yield 537 mg (52 %) 3 as a yellowish solid.

¹H NMR (599 MHz CDCl₃) δ (ppm) = 8.57 (s, 1H), 7.96 (s, 1H), 6.56 (s, 1H), 6.16 (dd, ³J=5.9, ³J=7.3, 1H), 4.40 – 4.32 (m, 2H), 4.28 – 4.22 (m, 1H), 4.06 (dd, ³J=3.7, ³J=6.2, 1H), 3.80 – 3.77 (m, 1H), 3.75 (dd, ³J=2.5, ²J=9.7, 1H), 2.63 (ddd, ³J=2.3, ³J=5.8, ²J=13.5, 1H), 1.95 (ddd, ³J=5.9, ³J=7.4, ²J=13.4, 1H), 1.09 – 1.05 (m, 2H), 0.88 (s, 9H), 0.86 (s, 9H), 0.07 (2x s, 18H), 0.05 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ (ppm) = 165.0, 163.7, 154.1, 147.3, 95.5, 88.8, 89.0, 72.9, 63.32, 63.30, 42.6, 25.8, 25.7, 18.2, 18.0, 17.7, -1.4, -1.6, -1.7, -4.7, -4.9, -5.5, -5.6. HRMS (ESI+): calculated for C₁₇H₃₄N₃O₆Si₃ [M+H]⁺: 600.3315, found: 600.3319.

In a flame dried round bottom flask 100 mg 3 (0.17 mmol, 1.0 eq) were dissolved in 10 mL DCM and 500 µL TBAF (1M in THF, 0.50 mmol, 3.0 eq) added. The solution was stirred at room temperature for 3 h. Subsequently 1 mL TMSOMe were added and the reaction mixture stirred for 30 min. The solvents were evaporated in vacuo and the crude product purified by HPLC (0-25 % MeCN in 45 min) to yield 32 mg (69 %) caC as a colorless solid.
\[ ^1\text{H NMR (400 MHz, D}_2\text{O) } \delta (\text{ppm}) = 8.55 (s, 1H), 6.31 (t, 3^J=6.5, 1H), 4.51 (m, 1H), 4.13 (dd, 3^J=4.2, 3^J=8.1, 1H), 3.91 (dd, 3^J=3.5, 2^J=12.4, 1H), 3.83 (dd, 3^J=5.3, 2^J=12.5, 1H), 2.52 (ddd, 3^J=4.3, 3^J=6.4, 2^J=14.2, 1H), 2.41 – 2.32 (m, 1H). \]

\[ ^13\text{C NMR (101 MHz, D}_2\text{O) } \delta (\text{ppm}) = 170.5, 164.6, 156.3, 146.3, 103.0, 86.8, 86.4, 70.4, 61.2, 39.6. \]

HRMS (ESI+): calculated for C\(_{10}\)H\(_{14}\)N\(_3\)O\(_6\)\([\text{M+H]}^+\): 272.0877, found: 272.0878.

In a high pressure glass autoclave 100 mg 5 (0.28 mmol, 1.0 eq), 45 mg PPh\(_3\) (0.17 mmol, 0.6 eq) and 29 mg Pd\(_2\)(dba)\(_3\)*CHCl\(_3\) (0.03 mmol, 0.1 eq) were dissolved in 10 mL DMF. The autoclave was flushed with CO twice to remove residual air and subsequently the reaction stirred at a CO pressure of 3.5 bar at 60 °C. With a syringe pump 95 µL Bu\(_3\)SnH (0.34 mmol, 1.2 eq, dissolved in 900 µL toluene) were added through a septum at 0.1 mL per hour. After completion of the addition the reaction mixture was stirred additional 12 hours at 60 °C. Subsequently the CO was discharged and the solvent evaporated in vacuo. The crude product was purified by column chromatography (DCM/MeOH 9:1) to yield 25 mg (35 %) fC as a yellow solid.

\[ ^1\text{H NMR (400 MHz, D}_2\text{O/MeOD) } \delta (\text{ppm}) = 9.56 (s, 1H), 8.85 (s, 1H), 6.24 (t, 3^J=6.1, 1H), 4.48 (dt, 3^J=4.8, 3^J=6.5, 1H), 4.18 (dd, 3^J=4.6, 3^J=8.0, 1H), 3.96 (dd, 3^J=3.4, 2^J=12.6, 1H), 3.84 (dd, 3^J=4.9, 2^J=12.6, 1H), 2.62 (ddd, 3^J=4.9, 3^J=6.5, 2^J=14.1, 1H), 2.46 – 2.37 (m, 1H). \]

\[ ^13\text{C NMR (101 MHz, D}_2\text{O/MeOD) } \delta (\text{ppm}) = 190.3, 162.6, 155.2, 154.6, 105.7, 87.4, 87.1, 69.7, 60.6, 40.0. \]

HRMS (ESI+): calculated for C\(_{10}\)H\(_{14}\)N\(_3\)O\(_6\)\([\text{M+H]}^+\): 256.0928, found: 256.0928.
In a flame dried round bottom flask 16 mg fC (0.07 mmol, 1.0 eq) and 76 mg CeCl$_3$·7 H$_2$O (0.20 mmol, 3.0 eq) were dissolved in 3 mL methanol. To this solution 3 mg NaBH$_4$ (0.07 mmol, 1.0 eq) were added and the reaction mixture stirred at room temperature for 15 min. Subsequently the reaction mixture was evaporated to dryness and the crude product purified by reversed phase column chromatography (0-5% MeOH). Because the product contained a significant amount of salts it was desalted using a nucleoside desalting column (Waters Sep-Pak Plus Short tC18) to yield 9 mg hmC (53%) as a colorless solid.

$^1$H NMR (400 MHz, D$_2$O/MeOD) $\delta$ (ppm) = 7.83 (s, 1H), 6.16 (t, $^3$J=6.5, 1H), 4.42 – 4.25 (m, 3H), 3.95 (dd, $^3$J=3.7, $^3$J=8.5, 1H), 3.76 (dd, $^2$J=3.4, $^2$J=12.5, 1H), 3.67 (dd, $^3$J=4.8, $^2$J=12.5, 1H), 2.34 (ddd, $^3$J=4.1, $^2$J=6.4, $^2$J=14.0, 1H), 2.24 – 2.11 (m, 1H).

$^{13}$C NMR (101 MHz, D$_2$O/MeOD) $\delta$ (ppm) = 166.1, 158.3, 141.3, 107.8, 88.0, 87.3, 71.6, 62.3, 59.0, 41.0. HRMS (ESI-): calculated for C$_{10}$H$_{14}$N$_3$O$_5$ [M-H]: 256.0939, found: 256.0936.

In a high pressure glass autoclave 300 mg 5 (0.85 mmol, 1.0 eq), 24 mg PdCl$_2$(MeCN)$_2$ (0.09 mmol, 0.11 eq) and 296 µL DIPEA (1.70 mmol, 2.0 eq) were
dissolved in 10 mL TMS-Et-OH. The autoclave was flushed with CO twice to remove residual air and subsequently the reaction stirred at a CO pressure of 3.5 bar at 60 °C for 24 h. After completion of the reaction the CO was discharged and the solvent evaporated in vacuo. The crude product was purified by column chromatography (DCM/MeOH 19:1) to yield 70 mg (22 %) 6 as a colorless oil.

$^1$H NMR (400 MHz, MeOD) $\delta$ (ppm) = 9.05 (s, 1H), 6.19 (t, $^3$J=6.1, 1H), 4.42 – 4.32 (m, 3H), 4.00 (q, $^3$J=3.5, 1H), 3.84 (dd, $^3$J=3.4, $^2$J=11.9, 1H), 3.76 (dd, $^3$J=3.5, $^2$J=12.0, 1H), 2.48 (ddd, $^3$J=4.6, $^3$J=6.3, $^2$J=13.7, 1H), 2.20 (dt, $^3$J=6.1, $^{2v}$J=13.7, 1H), 1.13 (ddd, $^3$J=1.2, $^3$J=6.7, $^2$J=8.6, 2H), 0.08 (s, 9H).

$^{13}$C NMR (101 MHz, MeOD) $\delta$ (ppm) = 166.4, 165.4, 156.7, 149.9, 97.5, 89.4, 88.7, 71.7, 64.6, 62.4, 42.80, 18.36, -1.32. HRMS (ESI+): calculated for C$_{15}$H$_{26}$N$_3$O$_6$Si$^+$ [M+H]$^+$: 372.1585, found: 372.1587.

In a polypropylene tube 70 mg 6 (0.19 mmol, 1.0 eq) were dissolved in 7 mL DCM, subsequently 76 µL pyridine (0.94 mmol, 5.0 eq) and 73 µL HF*pymidine (70 % HF, 2.83 mmol, 15.0 eq) were added and the reaction mixture stirred 14 h at room temperature. 500 µL TMSOMe were added and the reaction mixture stirred another 30 min, diluted with DCM and extracted with 20 mL H$_2$O. The aqueous layer was evaporated to dryness and the crude product purified by HPLC (0-25 % MeCN in 45 min) yielding 7 mg (11 %) caC.

$^1$H NMR (400 MHz, D$_2$O) $\delta$ (ppm) = 8.55 (s, 1H), 6.31 (t, $^3$J=6.5, 1H), 4.51 (m, 1H), 4.13 (dd, $^3$J=4.2, $^3$J=8.1, 1H), 3.91 (dd, $^3$J=3.5, $^2$J=12.4, 1H), 3.83 (dd, $^3$J=5.3, $^2$J=12.5, 1H), 2.52 (ddd, $^3$J=4.3, $^3$J=6.4, $^2$J=14.2, 1H), 2.41 – 2.32 (m, 1H). $^{13}$C NMR (101 MHz, D$_2$O) $\delta$ (ppm) = 170.5, 164.6, 156.3, 146.3, 103.0, 86.8, 86.4, 70.4, 61.2, 39.6. HRMS (ESI+): calculated for C$_{10}$H$_{14}$N$_3$O$_6$ Si$^+$ [M+H]$^+$: 272.0877, found: 272.0878.
In a polypropylene tube 143 mg 4 (0.25 mmol, 1.0 eq) were dissolved in 14 mL EtOAc, subsequently 149 µL pyridine (1.85 mmol, 7.5 eq) and 141 µL HF*pyridine (70 % HF, 5.41 mmol, 22.0 eq) were added and the reaction mixture stirred 14 h at room temperature. During this time a white solid crashed out. 1 mL TMSOMe were added and the reaction mixture stirred another 30 min. Subsequently the solid was collected by centrifugation (4000 rpm, 15 min). The product was subjected to HPLC purification (0-25 % MeCN in 45 min) to yield 43 mg hmU (70 %).

\(^1\)H NMR (400 MHz, D\(_2\)O) \(\delta\) (ppm) = 7.87 (d, \(^4\)J=0.7, 1H), 6.28 (t, \(^3\)J=6.7, 1H), 4.45 (dt, \(^3\)J=4.0, \(^3\)J=7.6, 1H), 4.36 (d, \(^4\)J=0.6, 2H), 4.02 (dd, \(^3\)J=4.0, \(^3\)J=7.9, 1H), 3.84 (dd, \(^3\)J=3.5, \(^2\)J=12.4, 1H), 3.76 (dd, \(^3\)J=4.8, \(^2\)J=12.4, 1H), 2.44 – 2.29 (m, 2H). \(^13\)C NMR (101 MHz, D\(_2\)O) \(\delta\) (ppm) = 167.0, 153.4, 140.3, 114.8, 87.8, 86.6, 71.6, 62.3, 57.8, 40.06. HRMS (ESI-): calculated for C\(_{10}\)H\(_{13}\)N\(_2\)O\(_6\) \([M-H]^-\) 257.0779, found: 257.0781.
Oligonucleotide Synthesis

was performed on an Expedite 8909 Nucleic Acid Synthesis System (*PerSeptive Biosystems*) using standard DNA synthesis conditions. Phosphoramidites for hmdC, dA, dC, dG, dT and CPG carriers were obtained from *Glen Research*. The terminal DMT protecting group was kept on the oligonucleotides after synthesis and removed after cleavage from the resin (see Deprotection and purification). Except for hmC standard coupling conditions were used. For hmC coupling times were doubled to ensure good yields.

Deprotection and purification:

Deprotection and cleavage of the oligonucleotides from the CPG carrier was carried out in a mixture of saturated ammonia solution in water (7 M) and ethanol (3:1) at 60 °C for 60 hours. DNA purification was conducted on analytical and preparative HPLC (*Waters* or *Merck Hitachi*) using *Nucleosil* columns (250 * 4 mm, C18ec, particle size 3 µm or 250 * 10 mm, C18ec, 5 µm) from *Machery-Nagel*. The applied buffer was 0.1 M triethylammoniumacetate in water / 0.1 M triethylammoniumacetate in 80 % aqueous MeCN. The fractions were checked for purity by analytical HPLC and MALDI-MS. The purified oligonucleotides were concentrated *in vacuo* using a *Savant Speed Vac*. The oligonucleotides still containing the trityl group were deprotected by addition of 100 µL of an 80% acetic acid solution. After incubation at r.t. for 20 min at room temperature 100 µL of water together with 60 µL of a 3 M solution of sodium acetate were added. The oligonucleotides were desalted with *Sep-Pak®* cartridges (*Waters*) prior to use.

The following sequence was used for the immunohistology-competition experiments:

5’ GTA GCC AGG TCG CAC GCG TGC TAX GAT GCG AGA CTG C 3’ X = hmC
